Lithium citrate
Lithium citrate is a lithium supplement that reduces excess brain N-acetylaspartate (NAA) in Canavan disease. Canavan disease is an autosomal recessive leukodystrophy caused by mutations in the aspartate acylase (ASPA) gene, which catalyzes the hydrolysis of N-acetylaspartate (NAA) to acetate and aspartate[1].
Product Specifications
CAS Number
[919-16-4]
Product Name Alternative
Litarex
UNSPSC
12352211
Hazard Statement
H302, H315, H319, H335
Target
Others
Type
Reference compound
Related Pathways
Others
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/lithium-citrate.html
Purity
98.0
Solubility
10 mM in DMSO
Smiles
O=C(CC(C(O[Li])=O)(CC(O[Li])=O)O)O[Li]
Molecular Formula
C6H5Li3O7
Molecular Weight
209.92
Precautions
H302, H315, H319, H335
References & Citations
[1]Mitra Assadi, et al. Lithium citrate reduces excessive intra-cerebral N-acetyl aspartate in Canavan disease. Eur J Paediatr Neurol. 2010 Jul;14 (4) :354-9.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
Launched
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
500282 10 µg
MSSK1, Recombinant, Human, GST-Tag (Muscle-specific Serine Kinase 1, STK23, SRPK3, SRSF Protein Kinase 3) discontinued
Ask
View Details 
MBS6198488-01 0.1 mL
TSC22D1 (TSC22 Domain Family, Member 1, DKFZp686O19206, MGC17597, RP11-269C23.2, TGFB1I4, TSC22) (MaxLight 405)
Ask
View Details 
MBS6198488-02 5x 0.1 mL
TSC22D1 (TSC22 Domain Family, Member 1, DKFZp686O19206, MGC17597, RP11-269C23.2, TGFB1I4, TSC22) (MaxLight 405)
Ask
View Details 